Intellia Therapeutics (Intellia Therapeutics) EBIT : $-517.34 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Intellia Therapeutics EBIT?

Intellia Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-114.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-517.34 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Intellia Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 was -114.45%. Intellia Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -299.78%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Intellia Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -34.21%.

Intellia Therapeutics EBIT Historical Data

The historical data trend for Intellia Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics EBIT Chart

Intellia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-106.37

-136.58

-267.85

-458.16

-515.29

Intellia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-111.96	-132.33	-131.11	-139.89	-114.00

Competitive Comparison of Intellia Therapeutics's EBIT

For the Biotechnology subindustry, Intellia Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intellia Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's EV-to-EBIT falls into.

Intellia Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-517.34 Mil.

Intellia Therapeutics (NAS:NTLA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Intellia Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-456.012 * ( 1 - 0% )	/	( (370.001	+	426.879)	/ 2 )
=	-456.012	/	398.44
=	-114.45 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1300.977	-	47.854	-	( 912.223	-	max(0, 115.208	-	998.33	+	912.223	))
=	370.001

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1259.589	-	46.579	-	( 791.294	-	max(0, 97.912	-	884.043	+	791.294	))
=	426.879

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Intellia Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-456.012	/	( ( (148.135 + max(-10.502, 0))	+	(142.499 + max(13.6, 0)) )	/	2 )
=	-456.012	/	( ( 148.135	+	156.099 )	/	2 )
=	-456.012	/	152.117
=	-299.78 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(36.456	+	0	+	49.651)	-	(47.854	+	22.14	+	26.615)
=	-10.502

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(36.427	+	0	+	56.322)	-	(46.579	+	22.184	+	10.386)
=	13.6

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Intellia Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-517.336	/	1512.455
	=	-34.21 %

Intellia Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Intellia Therapeutics (Intellia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (NAS:NTLA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

38I:Germany

Address

40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Executives

Laura Sepp-lorenzino	officer: EVP, Chief Scientific Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
James Basta	officer: EVP, General Counsel	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Derek Hicks	officer: EVP, Chief Business Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET SUITE 130, CAMBRIDGE MA 02139
Eliana Clark	officer: EVP, Chief Technical Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
David Lebwohl	officer: EVP, Chief Medical Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Glenn Goddard	officer: See Remarks	C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
John M. Leonard	director, officer: President and CEO	C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
William J Chase	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
John F Crowley	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Georgia Keresty	director	C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Caroline Dorsa	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Jose E Rivera	officer: EVP, General Counsel	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Andrew Schiermeier	officer: EVP, Chief Operating Officer	C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET STE 130, CAMBRIDGE MA 02139